News articles about Avanir Pharmaceuticals (NASDAQ:AVNR) have trended somewhat positive on Thursday, according to Accern Sentiment. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Avanir Pharmaceuticals earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave news coverage about the healthcare company an impact score of 43.6673593038556 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
ILLEGAL ACTIVITY WARNING: “Avanir Pharmaceuticals (NASDAQ:AVNR) Receives Media Impact Rating of 0.16” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.tickerreport.com/banking-finance/2798702/avanir-pharmaceuticals-nasdaqavnr-receives-media-impact-rating-of-0-16.html.
Avanir Pharmaceuticals Company Profile
AVANIR Pharmaceuticals, Inc (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system. It also has a number of partnered programs in other therapeutic areas.
Receive News & Ratings for Avanir Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanir Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.